Active, not recruitingPhase 1NCT03749187

BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Studying Glioblastoma

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of California, San Francisco
Principal Investigator: Sabine Mueller, MD, PhD
University of California, San Francisco
Intervention: PARP Inhibitor BGB-290(drug)
Enrollment: 78 enrolled
Eligibility: 13-39 years · All sexes
Timeline: 2019 – 2029

Study locations (11)

Children's Hospital Los Angeles, Los Angeles, California, United States
University of California, San Francisco, San Francisco, California, United States
Yale University, New Haven, Connecticut, United States
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Washington University School of Medicine, St Louis, Missouri, United States
Joseph M. Sanzari Children's Hospital at Hackensack University Medical Center, Hackensack, New Jersey, United States
Duke University Medical Center, Durham, North Carolina, United States
Oregon Health and Science University, Portland, Oregon, United States
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Collaborators

BeiGene USA, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03749187 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma →

← Back to all trials